Gli studenti sono ricevuti il Martedì dalle ore 11:30 alle 13:30 ed il Mercoledì dalle ore 12:00 alle 13:00. E' vivamente consigliato di prendere appuntamento via e-mail o telefonica.
Renato Corradetti si è laureato in Medicina e Chirurgia (1977) e specializzato in Neurologia (1982) presso l' Università di Firenze.Ricercatore Confermato (1981-1992), Professore Associato di Farmacologia (1992-2001). Dal 2001 è stato Professore Ordinario di Farmacologia. Dal 2024 è Professore Ordinario Emerito dell'Ateneo di Firenze.
Il suo campo di ricerca è la modulazione farmacologica della neurotrasmissione e della plasticità sinaptica (long-term potentiation, LTP) nel SNC utilizzando metodologie elettrofisiologiche (in vitro) e neurochimiche, spesso associate. Ha studiato il ruolo di numerosi neurotrasmettitori (adenosina, 5-HT, glutammato e GABA) nella neurotrasmissione cerebrale in ratti adulti, ma anche durante lo sviluppo e/o stati patologici (condizioni similepilettiche, anossia).
Legenda
Renato Corradetti graduated in Medicine and Surgery (1977) and specialized in Neurology (1982) at the University of Florence.He was appointed as Researcher (1981-1992) and Associate Professor of Pharmacology at the University of Florence (1992-2001). From 2001 up to 2023 he was Full Professor of Pharmacology in the Course of Medicine and Surgery of the Florence University. From 2024 he is Emeritus Professor.
Renato Corradetti obtained the Degrees of M.D. (1977) and of Specialist in Neurology (1982) at Florence University. Researcher (1981-1992), Associate Professor of Pharmacology (1992-2001) he is Professor of Pharmacology at Florence University. His research field is the pharmacological modulation of neurotransmission and synaptic plasticity (long-term potentiation: LTP) in the CNS using electrophysiological and neurochemical in vitro approaches, often in combination. The role of a number of neurotransmitters (adenosine, 5-HT, glutamate, GABA) in hippocampal neurotransmission in adult rats and during development and/or in pathological states (epileptic-like conditions, anoxia) have been investigated. Furthermore, neurophysiological and neurochemical correlates of LTP as well as the effects of several drugs on synaptic plasticity have been studied in detail, including the inhibitory action of 5-HT on LTP induction and the pharmacological identification of 5-HT receptors involved therein. The electrophysiological effects of novel antagonists at 5-HT3 (Itasetron) and 5-HT1A (WAY 100635) receptors on neurotransmission in the hippocampus and raphe have been characterised. Recently, hisresearch has been focussed on the study of the mechanisms of (auto)regulation of serotonergic neuron activity by somatodendritic 5-HT1A receptors (termed autoinhibition). Using a transgenic mouse that overexpress 5-HT1A receptors selectively in serotonergic neurons of the Raphe (Htr1ARO mouse line), described the appearance of a phenotype that could model the Sudden Infant Death Syndrome (SIDS) and part of the ongoing research is directed in understanding the physiological mechanisms that are impaired by 5-HT1A receptor overexpression and are potentially correlated with SIDS. In parallel, other mechanisms implicated in physiological autoinhibition (i.e. 5-HT synthesis, re-uptake, and metabolism) are under investigation using transgenic mice that bear risk factors for human pathology (e.g. TpH2 or SERT impairment for depression). Since 1985, Prof. Corradetti received national and local grants (from MURST, CNR, University of Florence, ECRF) as well as from the European Commission: BIO-CT96-0752 and QLG3-2002-00809,LSHM-CT2004-503474
Prof. Corradetti's research field is the pharmacological modulation of neurotransmission and synaptic plasticity (long-term potentiation: LTP) in the CNS using electrophysiological and neurochemical in vitro approaches, often in combination. During his activity he has studied the role of a number of neurotransmitters (adenosine, 5-HT, glutamate, GABA) in brain neurotransmission in adult rats and during development and/or in pathological states (epileptic-like conditions, anoxia) as well as pharmacological mechanisms of action of neuropsychiatric drugs.
